Search Within

Michael Morris

Formats
  1. Meeting Abstract (273)
  2. Journal Article (266)
  3. Review (19)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (580)
  2. Genitourinary Oncology Service (580)
  3. Solid Tumor Oncology Division (580)
  4. Radiology, Department of (163)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (140)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (21)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (238)
  2. Journal of Nuclear Medicine (43)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (248)
  2. American Association for Cancer Research (43)
  3. Society of Nuclear Medicine (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (39)
  6. Elsevier Inc. (27)

More Publishers

Results (580)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J. A.; O'Donoghue, J. A.; Humm, J.; Lyashchenko, S. K.; Haupt, E. C.; Bander, N. H.; Tagawa, S. T.; Holland, J. P.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study
    Meeting Abstract

    Fleming, M. T.; Rathkopf, D. E.; Gibbons, J.; Peterson, A. C.; Hannah, A.; Forer, D.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial
    Meeting Abstract

    Araujo, J. C.; Trudel, G. C.; Saad, F.; Armstrong, A. J.; Yu, E. Y.; Bellmunt, J.; Wilding, G.; McCaffrey, J.; Serrano, S. V.; Matveev, V.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Risk assessment for severe hypocalcemia requiring hospitalization with denosumab
    Meeting Abstract

    Autio, K. A.; Farooki, A.; Glezerman, I.; Chan, A.; Barr, H. C.; Seyboth, B. M.; Schneider, C. W.; Heller, G.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study
    Meeting Abstract

    Morris, M. J.; Hammers, H. J.; Sweeney, C.; Antonarakis, E. S.; Cho, S. Y.; Pandit-Taskar, N.; Jacene, H.; Bloma, M.; Aksnes, A. K.; O'Bryan-Tear, C. G.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib
    Meeting Abstract

    Fox, J. J.; Haupt, E. C.; Humm, J.; Autio, K. A.; Rathkopf, D. E.; Vargas, H. A.; Schöder, H.; Hricak, H.; Larson, S. M.; Scher, H. I.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer
    Meeting Abstract

    Fleming, M. T.; Rathkopf, D. E.; Gibbons, J.; Peterson, A. C.; Hannah, A.; Forer, D.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod
    Meeting Abstract

    Armstrong, A. J.; Kaboteh, R.; Carducci, M. A.; Damber, J. E.; Stadler, W. M.; Mats, H.; Edenbrandt, L.; Forsberg, G.; Nordle, O.; Pili, R.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer
    Meeting Abstract

    Halabi, S.; Lin, C. Y.; Kelly, W. K.; Fizazi, K.; Moul, J. W.; Kaplan, E.; Morris, M. J.; Small, E. J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save